Pular para o conteúdo principal

ETHNOS_APP

Início • Busca • Periódicos • Lista 0

Benoît Rive

Dados Biográficos

ID7592283
NOMEBenoît Rive
PRENOMESBenoît
SOBRENOMERive
ASSINATURARIVE B
AFILIAÇÕESJanssen (France)
VERIFICADONão
TOTAL DE OBRAS2
TOTAL DE CITAÇÕES0
TOTAL COMO AUTOR2
TOTAL COMO EDITOR0
PRIMEIRO ANO DE PUBLICAÇÃO2023
ANO MAIS RECENTE DE PUBLICAÇÃO2024
ÍNDICE H0
  • Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission

    Open Access•Albino J Oliveira-Maia, Benoît Rive et al.•ARTICLE•Frontiers in Psychiatry•2024

    For patients with TRD, esketamine NS had a significant functional benefit versus RWT after 6 months of treatment. Irrespective of treatment, achievement of clinical response or remission was insufficient to attain functional remission. Nevertheless, clinical remission increased the likelihood of achieving functional remission, further supporting an important role for clinical remission in for the path towards functional recovery

  • Iceberg study

    Open Access•Albino J Oliveira-Maia, Joachim Morrens et al.•ARTICLE•Frontiers in Psychiatry•2023

    ICEBERG supports that, at 6 months, esketamine NS has a substantial and significant benefit over RWT for patients with TRD. While results may be affected by unobserved confounding factors, threshold analyses suggested these were unlikely to impact the study conclusions.To view an animated summary of this publication, please click on the Supplementary video

Sem obras proeminentes nesta página.

  • Iceberg study

    Open Access•Albino J Oliveira-Maia, Joachim Morrens et al.•ARTICLE•Frontiers in Psychiatry•2023

    ICEBERG supports that, at 6 months, esketamine NS has a substantial and significant benefit over RWT for patients with TRD. While results may be affected by unobserved confounding factors, threshold analyses suggested these were unlikely to impact the study conclusions.To view an animated summary of this publication, please click on the Supplementary video

  • Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission

    Open Access•Albino J Oliveira-Maia, Benoît Rive et al.•ARTICLE•Frontiers in Psychiatry•2024

    For patients with TRD, esketamine NS had a significant functional benefit versus RWT after 6 months of treatment. Irrespective of treatment, achievement of clinical response or remission was insufficient to attain functional remission. Nevertheless, clinical remission increased the likelihood of achieving functional remission, further supporting an important role for clinical remission in for the path towards functional recovery

Anesthesia (2 obras) · Medicine (2 obras) · Nasal administration (2 obras) · Nasal spray (2 obras) · Pharmacology (2 obras) · Treatment of Major Depression (2 obras) · Confidence interval (1 obras) · Depression (economics (1 obras) · Geology (1 obras) · Ginkgo biloba and Cashew Applications (1 obras)

Ethnos_APP • Projeto Open Source • Licença MIT • Frontend v2.0.0 • Privacidade e Cookies • Documentação da API: api.ethnos.app/docs • Código da API: GitHub • DOI: 10.5281/zenodo.17049435 • Código do Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae